Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01422330 · ClinicalTrials.gov registry record · Phase 4
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected Patients
A Phase 4 study, sponsored by Janssen R&D Ireland.
- Completed
- Registry status
- Phase 4
- Development phase
- 211
- Enrollment target
NCT01422330: Completed Phase 4 study, sponsored by Janssen R&D Ireland.
NCT01422330 is a Phase 4 study that has completed, run by Janssen R&D Ireland. The registered enrollment target is 211 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (59% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01422330, a Phase 4 study, has completed, sponsored by Janssen R&D Ireland.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 211 participants
- Enrollment target
Study Summary
The purpose of this study is to learn more about the safety and tolerability of etravirine. Etravirine is a type of non-nucleoside reverse transcriptase inhibitor (NNRTI) which has shown high activity against wild-type human immunodeficiency virus (HIV-1), and HIV strains resistant to other non-nucleotide agents.
Interventions
- DRUG Etravirine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 211 participants |
| Start Date | 2011-09 |
| Est. Completion | 2013-11 |
| Phase | Phase 4 |
What the finished NCT01422330 record still lists
NCT01422330 is an interventional study that assigns participants to a tested intervention. The registered 211 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (59% lower).
The record links to 0 conditions, and to 1 intervention - of which Etravirine is the first listed.
NCT01422330 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01422330 about?
NCT01422330 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected Patients". The purpose of this study is to learn more about the safety and tolerability of etravirine. Etravirine is a type of non-nucleoside reverse transcriptase inhibitor (NNRTI) which has shown high activity against wild-type human immunodeficiency virus (HIV-1), and HIV strains resistant to other non-nucl...
What is the current status of trial NCT01422330?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 211 participants. The study started on 2011-09. Estimated completion is 2013-11.
What interventions are being tested in trial NCT01422330?
The interventions under investigation include: Etravirine (DRUG).
Who is sponsoring clinical trial NCT01422330?
This trial is sponsored by Janssen R&D Ireland, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01422330's enrollment target sits among peer trials
211 398th of 2000 higher than 1,603 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06698796 · 211 participants · Phase 3
A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies
- NCT04228978 · 212 participants · NA
Promote Weight Loss in Obese Peripheral Artery Disease (PAD) Patients to Prevent Mobility Loss
- NCT04725721 · 212 participants · NA
Testing FIRST in Youth Outpatient Psychotherapy
- NCT06257576 · 212 participants · Phase 3
Function of Tamsulosin in Older Males Undergoing Surgery with Indwelling Catheter
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia